Introduction
A complex disorder resulting from the combined effects of multiple environmental and genetic factors, prostate cancer is the second-leading cause of cancer death in men. 1 The underlying etiology of prostate cancer is still poorly understood. Genome-wide association studies on the genetic etiology of cancer have discovered some heritability of different cancer types. 2 Single-nucleotide substitution, a kind of alteration in genetic sequence, can lead to cancer formation through biologically regulating a handful of molecular activities. play important roles in cancer development, invasion, and metastasis. 5 At the genetic level, a number of studies have been carried out to assess associations between polymorphisms of MMPs and prostate cancer risk, [6] [7] [8] [9] [10] [11] [12] [13] [14] but conclusions have been conflicting and inconclusive. For example, Srivastava et al found the MMP2 rs243865 polymorphism contributed to prostate cancer susceptibility, 10 while Adabi et al found no association between MMP2 rs243865 polymorphism and prostate cancer risk. 11 Individual studies with small samples may result in incorrect conclusions. Therefore, a comprehensive meta-analysis and systematic review were necessary to assess relationships between MMP polymorphisms and prostate cancer risk precisely.
Methods

Search strategy
The entire process of this meta-analysis and systematic review followed the guidelines of the PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement (Table S1) . 15 The databases PubMed, Embase, and Web of Knowledge were searched with the following search terms: (MMP OR MMPs OR matrix metalloproteinase OR matrix metalloproteinases) AND (polymorphism OR polymorphisms OR single nucleotide polymorphism OR single nucleotide polymorphisms) AND (prostate cancer OR prostate carcinoma). The last search was on August 3, 2018. Additional published data were identified by reviewing references listed in each article. The literature search was performed by two investigators independently. Disagreement was resolved by discussion.
Inclusion and exclusion criteria
Inclusion criteria for this study were a focus on associations between MMP polymorphisms and prostate cancer risk, case-control design, available frequency of each genotype provided in both case and control groups to calculate OR and corresponding 95% CI, and written in English. Exclusion criteria were reviews, editorials, comments, and animal studies and overlap with another included article.
Data extraction
Two investigators independently extracted author names, year of publication, country of origin, case-group sample type, source of control group, genotyping method, type of MMPs, names of polymorphisms, number of cases and controls, Hardy-Weinberg equilibrium (HWE) values, and frequency of genotypes. Consensus on extracted items was reached by discussion between the two investigators.
Quality assessment
The quality of each included study was assessed according to the quality-assessment criteria in Table S2 . 16 Quality scores of studies ranged from 0 to 15, and studies with scores ≥9 were regarded as being of high quality.
Statistical analysis
Meta-analysis was performed unless at least two studies concerning the same MMP polymorphism were included; otherwise, a systematic review was carried out. Figure 1 shows the selection process. A total of 26 articles were identified through the search strategy. [6] [7] [8] [9] [10] [11] [12] [13] [14] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Nine articles were removed based on the title or abstract, [17] [18] [19] [20] [21] [22] [23] [24] [25] and Figure 1 Flow diagram of study-selection process.
Results
Literature search and study characteristics
Articles identified through database seaching (n=25)
Articles screened based on title and abstract (n=26)
Articles screened based on full text (n=17)
Aritcle included in this paper (n=11) 30 and one did not provide available frequency of each genotype in either the case group or control group. 31 Ultimately, eleven articles encompassing 22 studies [6] [7] [8] [9] [10] [11] [12] [13] [14] 32, 33 and involving 12 polymorphisms were included in this paper. Their characteristics are listed in Table 1 . Definitions of comparison models for the studies are listed in Table S3 , and frequencies of genotypes from the meta-analysis and systematic review in Tables S4 and S5, respectively. Among the included studies, 13 studies with three polymorphisms (five for MMP1 rs1799750 involving 853 prostate cancer cases and 1,027 controls, six for MMP2 rs243865 involving 699 prostate cancer cases and 734 controls, and two for MMP7 rs11568818 involving 297 prostate cancer cases and 297 controls) were quantitatively synthesized for meta-analysis. 6, [8] [9] [10] [12] [13] [14] 32, 33 The remaining nine studies with nine polymorphisms (MMP2 rs2285053, MMP2 rs1477017, MMP2 rs17301608, MMP2 rs11639960, MMP3 1171-5A/6A, MMP3 1161A/G, MMP3 5356A/G, MMP9 rs17576, and MMP13 rs2252070) involving 2,054 prostate cancer cases and 2,138 controls could not be quantitatively synthesized, and so the systematic review was performed. 7, 8, 10, 11, 33 
Meta-analysis
The results of meta-analysis for MMP1 rs1799750 (Table 2, Figure 2 ) showed that no significant associations were found in overall people (homozygote model, OR Figure 2 ), no associations existed in any comparison model. Subgroups of tissue samples could not be assessed, because there was only one study included.
For the MMP2 rs243865 polymorphism (Table 3 , Figure 3 ), meta-analysis showed no significant associations were found in people overall (homozygote model, OR Figure 3 ). For MMP7 rs11568818 ( 
Heterogeneity analysis
For MMP1 rs1799750, MMP2 rs243865, and MMP7 rs11568818 polymorphisms, there was no obvious heterogeneity in any comparison model for people overall or for subgroup analyses (Tables 2-4) .
Publication-bias analysis
For MMP1 rs1799750, funnel plots ( Figure 5) For MMP7 rs11568818, publication-bias analysis was not conducted for the two studies involved.
Systematic review
In the systematic review (Table 5) , two polymorphisms (MMP3 1171-5A/6A and MMP9 rs17576) were reported to be associated with prostate cancer risk, while another seven polymorphisms (MMP2 rs2285053, MMP2 rs1477017, MMP2 rs17301608, MMP2 rs11639960, MMP3 1161A/G, MMP3 5356A/G, and MMP13 rs2252070) were not associated with prostate cancer risk.
Discussion
Srivastava et al showed that MMP2 rs243865 polymorphism contributed to prostate cancer susceptibility, 10 while Adabi et al showed no association between MMP2 rs243865 polymorphism and prostate cancer risk. 13 Therefore, a comprehensive meta-analysis and systematic review were necessary. As a powerful tool for summarizing different studies, metaanalysis and systematic review refer to the use of statistical techniques to integrate results of included studies. 
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Zhou and Zhu This meta-analysis of five studies for MMP1 rs1799750, six studies for MMP2 rs243865 and two studies for MMP7 rs11568818 demonstrated that MMP1 rs1799750, MMP2 rs243865 polymorphisms and MMP7 rs11568818 were not associated with prostate cancer. Subgroup analysis by case-group sample type confirmed that no associations existed in any comparison model. We attributed the negative conclusions of our meta-analysis to two factors: firstly, only articles in English were included, and thus other related articles failed to be included; and secondly, some lower-quality studies were included, resulting in unpersuasive conclusions.
Although this systematic review of nine studies involving nine polymorphisms revealed that MMP3 1171 5A/6A and MMP9 rs17576 were associated with prostate cancer risk, its conclusion needs more research to support it, because each polymorphism had only one study. MMP9 can produce prostate cancer indirectly via triggering TGFβ activation, because an increase in TGFβ signaling will lead to cancer development and progession. 34, 35 Cancer Management and Research 2018:10 submit your manuscript | www.dovepress.com
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We noticed two previous meta-analyses had investigated the relationships of MMP1 rs1799750 or MMP2 rs243865 and prostate cancer risk. 17, 18 We read these carefully with great interest. Neither included other MMP polymorphisms, except for MMP1 rs1799750 and MMP2 rs243865. 17, 18 For MMP2 rs243865, our meta-analysis did not enroll the study by Jacobs et al, because it did not provide available frequency of genotypes. 7 Conversely, both the previous meta-analyses included this study and thus concluded significant association. 17, 18 For MMP1 rs1799750, our paper enrolled two additional studies 32, 33 compared with one previous meta-analysis, 17 and obtained a similar result. The major strengths of our paper lie in focusing on the relationship between MMP polymorphisms and prostate cancer risk comprehensively and systematically.
Some limitations still existed in our paper. First, several included studies contained small samples, which could lead to unpersuasive conclusions. Second, departure from HWE was detected in some studies. Third, there was a lack of a unified criterion for including studies.
Conclusion
In summary, our paper shows that MMP polymorphisms are not associated with prostate cancer risk, except for MMP3 1171-5A/6A and MMP9 rs17576. However, it is necessary to conduct more large-scale and high-quality studies in future. Study selection 9 State the process for selecting studies (ie, screening, eligibility, included in systematic review, and if applicable included in the meta-analysis).
4
Data collection process 10 Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items 11
List and define all variables for which data were sought (eg, PICOS, funding sources) and any assumptions and simplifications made.
Risk of bias in individual studies
12
Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. Summary measures 13 State the principal summary measures (eg, risk ratio, difference in means). 5 Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (eg, I 2 ) for each meta-analysis.
5
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (eg, publication bias, selective reporting within studies).
5-6
Additional analyses 16 Describe methods of additional analyses (eg, sensitivity or subgroup analyses, metaregression) if done, indicating which were prespecified.
Results
Study selection 17
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
6
Study characteristics 18 For each study, present characteristics for which data were extracted (eg, study size, PICOS, follow-up period) and provide the citations.
6-7
Risk of bias within studies 19 Present data on risk of bias of each study, and if available any outcome-level assessment (see item 12).
Results of individual studies 20
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group; (b) effect estimates and confidence intervals, ideally with a forest plot. 
